loading
Precedente Chiudi:
$43.61
Aprire:
$43.73
Volume 24 ore:
2.84M
Relative Volume:
0.21
Capitalizzazione di mercato:
$88.20B
Reddito:
$47.70B
Utile/perdita netta:
$5.07B
Rapporto P/E:
17.47
EPS:
2.4784
Flusso di cassa netto:
$14.58B
1 W Prestazione:
-3.04%
1M Prestazione:
-6.52%
6M Prestazione:
-12.24%
1 anno Prestazione:
-18.83%
Intervallo 1D:
Value
$43.30
$43.93
Intervallo di 1 settimana:
Value
$43.27
$44.78
Portata 52W:
Value
$42.96
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Nome
Bristol Myers Squibb Co
Name
Telefono
(609) 252-4621
Name
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Dipendente
34,100
Name
Cinguettio
@BMSNEWS
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
BMY's Discussions on Twitter

Confronta BMY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
43.33 89.15B 47.70B 5.07B 14.58B 2.4784
Drug Manufacturers - General icon
LLY
Lilly Eli Co
830.78 728.24B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
193.03 459.63B 92.15B 25.12B 18.18B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
226.78 404.77B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
130.73 252.16B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
84.63 211.56B 63.43B 16.42B 14.72B 6.4861

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-08-05 Downgrade Daiwa Securities Outperform → Neutral
2025-04-22 Iniziato Cantor Fitzgerald Neutral
2025-04-22 Iniziato Piper Sandler Overweight
2024-12-16 Aggiornamento Jefferies Hold → Buy
2024-12-10 Ripresa BofA Securities Neutral
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-13 Aggiornamento Daiwa Securities Neutral → Outperform
2024-11-12 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-25 Downgrade Citigroup Buy → Neutral
2024-10-17 Iniziato Bernstein Mkt Perform
2024-07-29 Downgrade Barclays Overweight → Equal Weight
2024-03-11 Downgrade Societe Generale Buy → Hold
2024-02-06 Downgrade Redburn Atlantic Buy → Neutral
2024-01-03 Downgrade BofA Securities Buy → Neutral
2023-11-15 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-02 Downgrade Daiwa Securities Outperform → Neutral
2023-10-27 Downgrade BMO Capital Markets Outperform → Market Perform
2023-10-27 Aggiornamento HSBC Securities Reduce → Hold
2023-10-27 Downgrade William Blair Outperform → Mkt Perform
2023-10-20 Ripresa UBS Neutral
2023-07-14 Iniziato HSBC Securities Reduce
2023-07-10 Iniziato SVB Securities Market Perform
2023-06-28 Iniziato Daiwa Securities Outperform
2023-03-06 Iniziato Jefferies Hold
2023-01-17 Iniziato Cantor Fitzgerald Overweight
2022-11-18 Iniziato Credit Suisse Neutral
2022-10-10 Downgrade Guggenheim Buy → Neutral
2022-09-14 Downgrade Berenberg Buy → Hold
2022-06-03 Downgrade Raymond James Outperform → Mkt Perform
2022-04-06 Ripresa Morgan Stanley Underweight
2021-12-17 Iniziato Goldman Buy
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-11-01 Downgrade Argus Buy → Hold
2021-07-27 Ripresa Truist Buy
2021-04-30 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-04-13 Aggiornamento Truist Hold → Buy
2020-11-16 Aggiornamento Societe Generale Hold → Buy
2020-11-10 Ripresa Bernstein Mkt Perform
2020-11-06 Downgrade Gabelli & Co Buy → Hold
2020-10-19 Aggiornamento Guggenheim Neutral → Buy
2020-09-29 Iniziato Berenberg Buy
2020-07-28 Iniziato Raymond James Outperform
2020-04-02 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-03-23 Downgrade Societe Generale Buy → Hold
2020-02-27 Iniziato Barclays Equal Weight
2020-01-06 Ripresa Citigroup Buy
2019-12-13 Aggiornamento Argus Hold → Buy
2019-11-22 Ripresa Morgan Stanley Equal-Weight
2019-10-17 Ripresa BofA/Merrill Buy
2019-08-14 Aggiornamento Atlantic Equities Neutral → Overweight
2019-05-28 Iniziato Goldman Buy
2019-05-20 Downgrade Argus Buy → Hold
2019-05-03 Aggiornamento Barclays Equal Weight → Overweight
2019-05-03 Ripresa JP Morgan Overweight
2019-01-15 Aggiornamento Societe Generale Sell → Buy
2018-10-22 Downgrade Citigroup Buy → Neutral
Mostra tutto

Bristol Myers Squibb Co Borsa (BMY) Ultime notizie

pulisher
Oct 15, 2025

What machine learning models say about Bristol Myers Squibb CompanyWatch List & Fast Moving Stock Trade Plans - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga

Oct 15, 2025
pulisher
Oct 15, 2025

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform - BioSpace

Oct 15, 2025
pulisher
Oct 14, 2025

insitro, Bristol Myers Squibb extend ALS collaboration with AI focus - Investing.com

Oct 14, 2025
pulisher
Oct 14, 2025

insitro, Bristol Myers Squibb extend ALS collaboration with AI focus By Investing.com - Investing.com South Africa

Oct 14, 2025
pulisher
Oct 14, 2025

BMY Collaboration Advances ALS Treatment Development - GuruFocus

Oct 14, 2025
pulisher
Oct 14, 2025

$20M Added to insitro–Bristol Myers Squibb ALS Collaboration; Novel ALS Target Identified - Stock Titan

Oct 14, 2025
pulisher
Oct 14, 2025

Kardigan raises $254M to test cardio drugs from Sanofi, BMS and Ionis - Endpoints News

Oct 14, 2025
pulisher
Oct 14, 2025

11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region - PR Newswire UK

Oct 14, 2025
pulisher
Oct 14, 2025

Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review

Oct 14, 2025
pulisher
Oct 14, 2025

What Bristol-Myers Squibb (BMY)'s FDA Fast Track for Alzheimer’s Drug Means for Shareholders - simplywall.st

Oct 14, 2025
pulisher
Oct 14, 2025

Bristol Myers' $1.5 Billion RNA Gamble: Could Orbital Therapeutics Rewire Its Future? - Smartkarma

Oct 14, 2025
pulisher
Oct 14, 2025

What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report - inkl

Oct 14, 2025
pulisher
Oct 14, 2025

Analyzing net buyer seller activity in Bristol Myers Squibb Company Equity RightWeekly Investment Recap & Smart Investment Allocation Tips - newser.com

Oct 14, 2025
pulisher
Oct 13, 2025

Bristol-Myers Squibb (BMY): Strong Growth Pipeline Supports High-Yield Dividend - Yahoo Finance

Oct 13, 2025
pulisher
Oct 13, 2025

Why Top Investors Are Buying Bristol-Myers Squibb Co (BMY) - The Acquirer's Multiple

Oct 13, 2025
pulisher
Oct 13, 2025

Pharma companies announce direct-to-consumer sales and price cuts in US - Reuters

Oct 13, 2025
pulisher
Oct 13, 2025

Bristol Myers Faces Legacy Headwinds But Banks On Its Pipeline - Finimize

Oct 13, 2025
pulisher
Oct 13, 2025

Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight - GlobeNewswire Inc.

Oct 13, 2025
pulisher
Oct 13, 2025

Bispecifics in Oncology Market Statistics Expected to Experience Major Growth by 2040, According to DelveInsight | AstraZeneca, I-MAB Biopharm, BioNTech, Bristol Myers Squibb - Barchart.com

Oct 13, 2025
pulisher
Oct 13, 2025

Trend analysis for Bristol Myers Squibb Company this weekJuly 2025 Outlook & Weekly Setup with High ROI Potential - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration - BioSpace

Oct 13, 2025
pulisher
Oct 13, 2025

Mark Cuban’s Pharmacy Targets Drug Pricing Reform as AstraZeneca Invests $4.5 Billion in Virginia and Bristol Myers Squibb Acquires Orbital Therapeutics for $1.5 Billion - geneonline.com

Oct 13, 2025
pulisher
Oct 13, 2025

Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics (NYSE:BMY) - Seeking Alpha

Oct 13, 2025
pulisher
Oct 13, 2025

2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types - Business Wire

Oct 13, 2025
pulisher
Oct 13, 2025

Bristol Myers (BMY) Triggers Milestone Payment with SystImmune C - GuruFocus

Oct 13, 2025
pulisher
Oct 13, 2025

Bristol-Myers Squibb (BMY) Stock Analysis: Navigating a 20% Potential Upside Amidst a Robust Dividend Yield - DirectorsTalk Interviews

Oct 13, 2025
pulisher
Oct 13, 2025

SystImmune receives $250 million milestone payment from Bristol Myers Squibb - Investing.com

Oct 13, 2025
pulisher
Oct 12, 2025

Covington aids Bristol Myers Squibb on Orbital Therapeutics acquisition - ICLG.com

Oct 12, 2025
pulisher
Oct 11, 2025

Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus - Seeking Alpha

Oct 11, 2025
pulisher
Oct 11, 2025

Bristol-Myers Squibb (BMY): Exploring Valuation After Recent Share Price Declines - simplywall.st

Oct 11, 2025
pulisher
Oct 11, 2025

Bristol Myers Squibb: Value Emerges From Distress - Seeking Alpha

Oct 11, 2025
pulisher
Oct 11, 2025

Bristol Myers Squibb’s Alzheimer’s Drug, BMS-986446, Granted FDA Fast Track Status - Yahoo Finance

Oct 11, 2025
pulisher
Oct 11, 2025

Conning Inc. Has $33.17 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Fourpath Capital Management LLC Trims Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

CAR Ts for autoimmune ramp up: BMS buying Orbital for $1.5B - BioWorld MedTech

Oct 10, 2025
pulisher
Oct 10, 2025

BMS expands CAR-T portfolio with $1.5bn Orbital buyout - Pharmaceutical Technology

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers to buy Cambridge startup Orbital Therapeutics, building out cell therapy pipeline - The Boston Globe

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push | Business Information & News | FE - Westlaw Today

Oct 10, 2025
pulisher
Oct 10, 2025

What's Going On With Bristol Myers Squibb Stock Friday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition - Sahm

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Chart based analysis of Bristol Myers Squibb Company trendsEntry Point & Fast Moving Market Watchlists - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals

Oct 10, 2025
pulisher
Oct 10, 2025

BMS latest to enter in vivo CAR-T field with $1.5B Orbital buy - FirstWord Pharma

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push - Reuters

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers Squibb To Acquire Orbital Therapeutics - citybiz

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers makes $1.5B bid for Orbital Therapeutics - The Pharma Letter

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push By Reuters - Investing.com

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Bill - GuruFocus

Oct 10, 2025

Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general SNY
$50.27
price up icon 2.73%
drug_manufacturers_general PFE
$24.44
price up icon 0.41%
$120.29
price up icon 1.58%
$300.38
price up icon 0.97%
drug_manufacturers_general NVO
$57.14
price up icon 0.81%
drug_manufacturers_general MRK
$84.67
price up icon 0.71%
Capitalizzazione:     |  Volume (24 ore):